Biotech AI Hiring 2026: Where Bio Meets ML
Last updated: May 3, 2026 | By Devin Hornick
Biotech AI hiring in 2026 is its own market, with senior ML scientists clearing $245,000 to $325,000 base plus equity, and the supply gap sitting in candidates fluent in both protein modeling and production ML. The roles look like ML jobs on the org chart. They aren’t. The screening loop, the comp math, and the candidate pool all behave differently, and most biotech hiring managers are still running an interview process designed for either a pure ML engineer or a pure computational biologist. Neither one fits.
Three searches in the same week last quarter. A Series B oncology shop in Cambridge wanted a “machine learning lead.” A clinical-stage genomics company in South San Francisco wanted a “computational scientist.” A discovery-platform startup in Seattle wanted a “bio-AI engineer.” Three orgs, three reporting lines, three JDs that read like different industries.
The intake calls told a different story. The Cambridge VP of platform got 20 minutes in and said the part out loud: “honestly we just need someone who can take our cell painting data, fine-tune something useful on it, and not break when our med chem director asks why the model thought compound 47 was promising.” The South San Francisco hiring manager said almost the same thing in different words. The Seattle CTO said the same thing again. Same job. Three titles. Each company wrote the req through whichever internal function was nearest the problem. The bio side wrote a comp-bio req. The ML side wrote a generic MLE req. Neither described what closed.
I am Devin Hornick, a partner at KORE1. I sit a step back from individual searches and read the debrief notes when a biotech ML hire either lands well or falls apart inside the first six months. Across our AI/ML engineer staffing and biomedical engineering staffing practices, this hire is the one that breaks intake calls more than any other right now. The framework below is what the searches that close in eight weeks have in common.
One thing on the table first. KORE1 places ML and computational science talent into biotechs and pharma, and we earn a fee on it. The lens is honest about that. Most of what is below works whether the search comes through us or you run it in-house.
Why Biotech AI Hiring Became Its Own Market
The premise behind a generic ML hire is that a strong engineer can pick up a domain on the job. For most domains, that is roughly true. Recommendations, pricing, ad targeting, fraud, search ranking. Domain context is real but learnable. Six months in, a sharp engineer is operationally fluent.
Biotech doesn’t. The reason is not snobbery, and biology isn’t intrinsically harder than the other domains where MLEs land softly. The difference is that the cost of being wrong is much higher and the feedback loops are dramatically slower than in consumer-facing ML. A misranked search result costs a click. A bad lead optimization recommendation costs roughly $400K of medicinal chemistry budget, eight weeks of wet-lab time, and a slot in next quarter’s portfolio review that another program needed. The model is allowed to be wrong. The engineer is not allowed to be wrong about how wrong the model is allowed to be. That second skill comes from domain fluency, and it is not learnable in three months of self-study, no matter how strong the engineer.
The other reason biotech ML hiring split off is the supply side. The candidates who can do this work end-to-end overlap with two adjacent pools that are not large to begin with. Computational chemists with real ML reps. Computational biologists who can ship production code. Bioinformaticians who have done more than run pipelines. Those overlaps are thin. The 2023 Nature feature on industry demand for ML-skilled bioinformaticians covered the early version of this. The market has tightened since.
Demand has gone vertical. The Bureau of Labor Statistics projects 26% growth in computer and information research scientist roles through 2033, and a meaningful chunk of that growth is sitting inside life sciences companies that did not employ a single ML scientist five years ago. Recursion, Insitro, Isomorphic Labs, Genentech’s Prescient Design, every top-twenty pharma’s internal AI org, every preclinical platform company built around foundation models for chemistry or biology. Volume is real. Growing fast. The qualified pool is not.
The Four Profiles Biotech ML Reqs Actually Need
The first thing that goes wrong in a biotech AI search is that the hiring manager has a real need but uses a title that pulls the wrong pool. Four shapes show up over and over in the work that closes. Pick a lane before you write the JD.
| Profile | What They Actually Do | Where They Come From |
|---|---|---|
| Production ML engineer (bio-aware) | Owns the inference path from a trained model to a serving endpoint a benchtop scientist actually uses. Picks up biology context fast. Does not run novel modeling experiments. | Senior MLE roles at general tech, often with a graduate degree that touched biology, or a year inside a biotech already. |
| Foundation-model scientist | Pretrains or fine-tunes domain models for proteins, small molecules, single-cell, or imaging. Reads recent papers weekly. Writes the eval harness. | PhD in ML, computational biology, or computational chemistry, often with a postdoc at a discovery-platform shop or a top academic ML group. |
| Computational chemist or biologist who codes | Designs the experiment, picks the right model architecture, knows what the assay readout actually measures. Writes the analysis pipeline. Less production responsibility. | PhD in chemistry, biochemistry, or quantitative biology with five-plus years of applied ML on real campaigns. |
| Bio-data infrastructure engineer | Pipelines for high-content imaging, single-cell sequencing, mass spec, ELN-to-warehouse flows. Owns the data layer ML scientists train on. Often the most underpaid role in the org. | Data engineering background with a bioinformatics stint, or bioinformatics core staff who have grown into infrastructure. |
Most reqs describe profile two and budget for profile one, sometimes the reverse. The most underweighted of the four is the last one, the bio-data infrastructure engineer that nobody puts on the org chart until the foundation-model scientist is already six weeks into the role and complaining about the data layer. Without that clean data layer, the foundation-model scientist spends the first eight weeks debugging schema problems instead of fitting models. Multiple platform companies we have placed into solved this by hiring profile four before profile two, and their model timelines compressed by a factor we did not expect going in.
What the Comp Data Actually Says
Compensation is where outdated benchmarks cause the most visible damage in this search. The 2022-era assumption that “biotech pays less than tech” is wrong for this specific role by a wide margin, and reqs still anchored to it lose offers in the final round to clients who repriced two quarters ago. Equity-rich biotech ML packages compete head-on with FAANG-tier ML scientist offers now, and at the senior end the biotech offer often wins on total comp once the equity vests, particularly inside platform shops still inside their first growth round.
Bands below are pulled from five-plus active KORE1 search files closed or in-flight inside the last two quarters, cross-checked against publicly disclosed ranges from Levels.fyi, Built In, and what hiring leaders at clinical-stage and platform biotechs are actually paying. Run our Salary Benchmark Assistant for live numbers tied to your specific search.
| Role | Mid-Level Base | Senior Base | Notes |
|---|---|---|---|
| Production ML engineer (bio-aware) | $165K to $205K | $220K to $280K | Plus equity. Pulls 10 to 20% over generic MLE due to scarcity. |
| Foundation-model scientist | $200K to $245K | $245K to $325K | Top end at platform shops and well-funded preclinicals. Equity often makes the offer. |
| Comp chem / comp bio with ML | $175K to $215K | $215K to $285K | Equity weighted toward retention. PhDs at the senior end. |
| Bio-data infrastructure engineer | $155K to $195K | $200K to $255K | Underpriced relative to impact. Easiest leverage point on the org chart. |
Bay Area, Boston-Cambridge, and Seattle pay inside these bands. San Diego runs five to ten percent below. Research Triangle and Philadelphia run ten to fifteen below at the senior end. Remote-eligible offers from coastal biotechs trend toward the top of band, because the talent pool willing to take a fully remote role at a biotech (where the wet lab is a four-hour flight away) is meaningfully thinner than at a generic SaaS company hiring the same archetype. Wet-lab proximity costs real money.
Where the Talent Actually Lives
Five U.S. clusters carry roughly 80% of the biotech AI candidate pool. The rest is scattered across academic ML groups, pharma R&D centers, and a small but real remote-first cohort.
Boston and Cambridge sit at the top, anchored by the Kendall Square corridor and the Broad Institute alumni network. The intersection of MIT, Harvard, and a dense cluster of platform biotechs (Recursion’s Boston site, Vertex, Moderna, the entire Flagship portfolio) puts more multi-skill candidates inside a five-mile radius than any other market.
The Bay Area is second by volume but first by the senior end of the pool. South San Francisco’s Mission Bay cluster, the Stanford pipeline, and the Genentech Prescient Design alumni feed every preclinical platform company in California. Comp runs hottest here. So does competition.
San Diego, anchored by Torrey Pines and Sorrento Valley, has the dense computational chemistry pool that drug discovery shops keep returning to, with less foundation-model talent than Boston or the Bay but more applied campaign experience per candidate.
Seattle is the surprise of the last two years. Allen Institute, the University of Washington’s Baker Lab and Institute for Protein Design, plus the steady spillover from Amazon and Microsoft AI hires who have rotated into bio at the senior IC level. Younger pool. Technically strong.
Research Triangle and Philadelphia round out the top five, with the RTP pool tilted toward pharma R&D ML scientists and Philly biased toward clinical-trial AI and biostatistics-adjacent ML. The Philly market in particular is undervalued by recruiters who default to coastal sourcing.
The Screening Pattern That Catches Mis-Hires Early
The interview loop most biotechs run came from one of two ancestors. Either a generic MLE loop with a coding screen, a system design round, and a behavioral, or a comp-bio loop with a research presentation and a methods deep-dive that takes a full afternoon and produces nothing the hiring manager can compare across candidates. Both miss the actual hire.
The pattern that closes in our data has four specific rounds, and the order matters more than most clients believe going in.
Round one. Live exercise. Show the candidate a real, anonymized internal dataset (an assay readout, a cell-painting profile, a binding affinity table) and ask how they would approach a modeling question on it. Not solve it. Approach it. The signal is whether they ask about how the data was generated before they ask about the model. The candidates who go straight to “I’d try a transformer” are usually a no, regardless of how strong the profile reads on paper. The ones who ask about replicate count, batch effects, and what the assay actually measures are usually the hire. We had a senior candidate last fall, three Nature papers and a clean GitHub, who walked into round one and asked four batch-effect questions in the first six minutes. He had the offer the next morning.
Round two is a code review. Show them a 200-line piece of internal-style ML code (or a recent paper’s released model code, lightly modified) and have them read it aloud and critique. The signal here is whether they catch the kinds of mistakes that ship and break things. Schema drift. Silent data leakage between train and validation. A loss function that does not match the stated objective.
Round three is the wet-lab interface. 45 minutes with a senior wet-lab scientist or medicinal chemist, no slides. The chemist talks about a real project. The candidate asks questions. The chemist scores. We placed a senior foundation-model scientist last year who failed this round at one client (the chemist’s debrief read: “kept pulling the conversation back to attention layers, never asked me what we actually need”) and got hired six weeks later by another client for the same role on the same architecture. The difference was always whether the candidate could let a non-ML person lead.
Round four is the offer-readiness round. A 30-minute conversation with the hiring manager about scope, autonomy, and what the candidate actually wants to be doing in 18 months. Not a pitch. A read on whether the role and the candidate are actually aligned. Biotech AI roles diverge wildly inside the same title. A misalignment shows up by month four every time.
The clients who run this loop close in 6 to 9 weeks. The ones who run a generic MLE loop close in 12 to 16, and the offers go out to candidates who do not make it past the wet-lab round in their second six months and become a backfill problem.
Mistakes Biotech Hiring Managers Make in This Search
Not every miss is a search problem. Some are upstream of the recruiter and stay invisible until the hire has been on the team for three months. The list below is the short version of patterns we have watched repeat across more than two dozen biotech ML searches in the last eighteen months.
- Treating it as a tax on R&D rather than a function with a P&L impact. The role gets buried under a director who does not understand it, performance is measured against the wrong outcomes, and the hire leaves inside a year.
- Hiring a profile-two foundation-model scientist when the actual problem is a profile-one production engineer. The hire is bored inside three months and gone inside nine.
- Skipping the wet-lab round to “save time.” The hire who passes a generic MLE loop and never met a chemist before signing is the hire who pushes back on assay constraints in month two and erodes trust with the science org.
- Underpaying profile four. We have seen biotechs spend $260K base on a foundation-model scientist who then spends 60% of their first year wrestling with a data layer that a $185K data infra hire would have fixed in a quarter.
- Confusing publication record with shipped impact. Strong papers are a real signal at the foundation-model lane. They are not a signal at the production engineer lane, and reqs that conflate them attract the wrong pool.
- Running a remote-only search when the work has wet-lab handoffs. Possible. Just harder, and not the right default for most early-stage shops.
The retention math underneath all of this. KORE1’s 12-month placement retention sits at 92% across our practices. Inside the biotech AI subset, retention is higher when the four-round loop runs in full. Lower when round three is skipped. Skipping is the single most predictive failure mode we track.
Common Questions About Biotech AI Hiring
Do biotech AI hires really need a biology PhD?
For the foundation-model scientist and the comp-chem-with-ML lanes, usually yes, or a closely adjacent doctorate plus real campaign experience. For the production ML engineer and bio-data infrastructure lanes, no. Strong CS or applied math backgrounds with a year inside a biotech or a graduate-level project that touched biology will close those searches at every level we have run them. The PhD requirement gets defaulted into reqs where it does not actually fit, and that default narrows the funnel by 60% with no quality gain.
How long does a senior biotech ML hire actually take?
Six to nine weeks for the well-defined searches that pick a lane and run the four-round loop. Twelve to sixteen weeks for searches still figuring out which profile they need. Searches that change scope mid-process can run six months and rarely close at the original comp band.
What about contract or contract-to-hire for these roles?
Contract staffing works well for the bio-data infrastructure profile and surprisingly well for production ML engineers brought in for a specific platform build. It works less well for foundation-model scientists, who tend to be invested in long-cycle research and are not easily moved on a six-month engagement. C2H is a strong middle path for senior ML scientists where culture fit is the main risk.
Are AI-native biotechs paying more than legacy pharma?
At the senior end, yes. AI-native platforms (Recursion, Insitro, Isomorphic, the next tier of clinical-stage discovery shops) compete on equity that occasionally beats legacy pharma cash by a wide margin, especially for the foundation-model scientist lane. Legacy pharma still wins on stability and benefits, and that matters more to candidates than recruiters tend to assume.
Where does generative chemistry sit on this map?
Inside the foundation-model scientist lane, with a strong tilt toward candidates who came out of computational chemistry. The work centers on de novo molecule generation, lead optimization with reinforcement-learning-from-property-feedback variants, and increasingly on closed-loop wet-lab integration. Comp at the top of this band runs at or above the foundation-model scientist range in the table above.
How do we screen for AI tool literacy without testing memorized syntax?
The strongest signal is a candidate who reviews and edits AI-generated code, prompts precisely, and pushes back when the output is wrong. Show them a 200-line piece of code that contains a subtle data-leakage bug or an objective-function mismatch and ask them to read it aloud. The candidates who use AI well day-to-day catch these kinds of mistakes faster than the ones who do not.
Where to Start If You Are Hiring
Start with a 30-minute scoping call before the JD gets written. Pick the lane. Decide which of the four profiles the actual hire is. Profile one. Profile two. Profile three. Profile four. Each pulls a different pool. Each carries a different price. Conflating them stalls these searches at week ten.
If you are inside that scoping conversation and want a second read on which lane your real need fits, talk to our practice team. We run these searches across AI/ML staffing and biomedical engineering staffing together, and the lane question is answered in the first 20 minutes more often than not.